Home Applications 218160 Application 218160
Type NDA
Sponsor ELI LILLY AND CO Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 RETEVMO SELPERCATINIB TABLET;ORAL 40MG Yes No 002 RETEVMO SELPERCATINIB TABLET;ORAL 80MG Yes No 003 RETEVMO SELPERCATINIB TABLET;ORAL 120MG Yes No 004 RETEVMO SELPERCATINIB TABLET;ORAL 160MG Yes Yes 005 RETEVMO SELPERCATINIB CAPSULE;ORAL 40MG No No 006 RETEVMO SELPERCATINIB CAPSULE;ORAL 80MG No No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 4 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N218160-001 RETEVMO SELPERCATINIB 40MG TABLET / ORAL RLD 2024-04-10 N218160-002 RETEVMO SELPERCATINIB 80MG TABLET / ORAL RLD 2024-04-10 N218160-003 RETEVMO SELPERCATINIB 120MG TABLET / ORAL RLD 2024-04-10 N218160-004 RETEVMO SELPERCATINIB 160MG TABLET / ORAL RLD, RS 2024-04-10
Orange Book patents# Current patent rows page 1 of 1 · 68 matching rows.
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 80 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 2 · 76 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N218160-001 RETEVMO 40MG TABLET / ORAL RLD 2024-04-10 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 RETEVMO 80MG TABLET / ORAL RLD 2024-04-10 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-003 RETEVMO 120MG TABLET / ORAL RLD 2024-04-10 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-004 RETEVMO 160MG TABLET / ORAL RLD, RS 2024-04-10 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N218160-001 RETEVMO 40MG TABLET / ORAL RLD 2024-04-10 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218160-002 RETEVMO 80MG TABLET / ORAL RLD 2024-04-10 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218160-003 RETEVMO 120MG TABLET / ORAL RLD 2024-04-10 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218160-004 RETEVMO 160MG TABLET / ORAL RLD, RS 2024-04-10 c2088c7a36db…2026-09-14 22:38:34 2026-08 N218160-001 RETEVMO 40MG TABLET / ORAL RLD 2024-04-10 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218160-002 RETEVMO 80MG TABLET / ORAL RLD 2024-04-10 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218160-003 RETEVMO 120MG TABLET / ORAL RLD 2024-04-10 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218160-004 RETEVMO 160MG TABLET / ORAL RLD, RS 2024-04-10 84e616aacf4f…2026-08-18 06:07:40 2026-07 N218160-001 RETEVMO 40MG TABLET / ORAL RLD 2024-04-10 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218160-002 RETEVMO 80MG TABLET / ORAL RLD 2024-04-10 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218160-003 RETEVMO 120MG TABLET / ORAL RLD 2024-04-10 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218160-004 RETEVMO 160MG TABLET / ORAL RLD, RS 2024-04-10 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N218160-001 RETEVMO 40MG TABLET / ORAL RLD 2024-04-10 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218160-002 RETEVMO 80MG TABLET / ORAL RLD 2024-04-10 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218160-003 RETEVMO 120MG TABLET / ORAL RLD 2024-04-10 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218160-004 RETEVMO 160MG TABLET / ORAL RLD, RS 2024-04-10 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218160-001 RETEVMO 40MG TABLET / ORAL RLD 2024-04-10 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218160-002 RETEVMO 80MG TABLET / ORAL RLD 2024-04-10 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218160-003 RETEVMO 120MG TABLET / ORAL RLD 2024-04-10 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218160-004 RETEVMO 160MG TABLET / ORAL RLD, RS 2024-04-10 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N218160-001 RETEVMO 40MG TABLET / ORAL RLD 2024-04-10 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N218160-002 RETEVMO 80MG TABLET / ORAL RLD 2024-04-10 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N218160-003 RETEVMO 120MG TABLET / ORAL RLD 2024-04-10 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N218160-004 RETEVMO 160MG TABLET / ORAL RLD, RS 2024-04-10 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N218160-001 RETEVMO 40MG TABLET / ORAL RLD 2024-04-10 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N218160-002 RETEVMO 80MG TABLET / ORAL RLD 2024-04-10 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N218160-003 RETEVMO 120MG TABLET / ORAL RLD 2024-04-10 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N218160-004 RETEVMO 160MG TABLET / ORAL RLD, RS 2024-04-10 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N218160-001 RETEVMO 40MG TABLET / ORAL RLD 2024-04-10 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N218160-002 RETEVMO 80MG TABLET / ORAL RLD 2024-04-10 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N218160-003 RETEVMO 120MG TABLET / ORAL RLD 2024-04-10 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N218160-004 RETEVMO 160MG TABLET / ORAL RLD, RS 2024-04-10 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N218160-001 RETEVMO 40MG TABLET / ORAL RLD 2024-04-10 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N218160-002 RETEVMO 80MG TABLET / ORAL RLD 2024-04-10 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N218160-003 RETEVMO 120MG TABLET / ORAL RLD 2024-04-10 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N218160-004 RETEVMO 160MG TABLET / ORAL RLD, RS 2024-04-10 03ed91905a0d…
Observed Orange Book patent history# Patent history page 1 of 28 · 1,084 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N218160-001 10112942 2037-10-10 Drug substance, Drug product 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 10137124 2037-10-10 U-3450 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 10137124 2037-10-10 U-3949 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 10137124 2037-10-10 U-3950 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 10137124 2037-10-10 U-3951 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 10172851 2037-10-10 U-3450 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 10172851 2037-10-10 U-3949 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 10172851 2037-10-10 U-3950 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 10172851 2037-10-10 U-3951 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 10112942*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 10137124*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 10172851*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 12138250 2038-10-10 U-3450 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 12138250 2038-10-10 U-3949 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 12138250 2038-10-10 U-3951 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 12138250 2038-10-10 U-3950 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-001 12138250*PED 2039-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10112942 2037-10-10 Drug substance, Drug product 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10137124 2037-10-10 U-3450 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10137124 2037-10-10 U-3949 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10137124 2037-10-10 U-3950 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10137124 2037-10-10 U-3951 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10172851 2037-10-10 U-3450 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10172851 2037-10-10 U-3949 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10172851 2037-10-10 U-3950 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10172851 2037-10-10 U-3951 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10112942*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10137124*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 10172851*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 12138250 2038-10-10 U-3450 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 12138250 2038-10-10 U-3951 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 12138250 2038-10-10 U-3950 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 12138250 2038-10-10 U-3949 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-002 12138250*PED 2039-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-003 10112942 2037-10-10 Drug substance, Drug product 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-003 10137124 2037-10-10 U-3450 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-003 10137124 2037-10-10 U-3949 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-003 10137124 2037-10-10 U-3950 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-003 10137124 2037-10-10 U-3951 2024-05-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218160-003 10172851 2037-10-10 U-3450 2024-05-09 d4dbc9d85df4…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 17 · 664 observed states.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join RETEVMO SELPERCATINIB Eli Lilly and Company 7fa848ba-a59c-4144-9f52-64d090f4d828 2026-09-11 Warnings, Adverse reactions Exact identifier application applno (NDA): 218160 application number: NDA218160
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents# Document, Submission type, Date table Document Submission type Date 84267 SUPPL 2025-11-21 84266 SUPPL 2025-11-21 84262 SUPPL 2025-11-21 84261 SUPPL 2025-11-21 81773 ORIG 2025-03-28 80646 SUPPL 2024-12-19 80639 SUPPL 2024-12-19 79767 SUPPL 2024-09-30 79766 SUPPL 2024-09-30 79760 SUPPL 2024-09-30 79759 SUPPL 2024-09-30 78786 SUPPL 2024-06-13 78778 SUPPL 2024-06-12 78113 ORIG 2024-04-12 78105 ORIG 2024-04-10